Wire · opportunities
Liquidia surges as United Therapeutics settlement removes key litigation risk
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
Liquidia settled a $381 million lawsuit with United Therapeutics, resolving patent and antitrust claims related to its lung disease drug Yutrepia, removing significant litigation risk. As part of the deal, Liquidia will cease promoting Yutrepia for PH-ILD but continue sales for PAH, paying United Therapeutics in installments through 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 14 Oct 2026.
◆ ◆ The Wire takeaway
Your lung disease drug market just opened with major legal risks cleared and US regulatory label simplified. You need to reposition for pure PAH market growth and accelerate clinical pipeline to seize the moment.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 14 Oct 2026
◆ Related on Wire
◆ Topics